Acurx Pharmaceuticals Inc... (ACXP)
NASDAQ: ACXP
· Real-Time Price · USD
5.31
0.59 (12.62%)
At close: Aug 25, 2025, 3:59 PM
5.30
-0.15%
After-hours: Aug 25, 2025, 07:57 PM EDT
Acurx Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -10M | -11.87M | -14.1M | -16.44M | -16.73M | -16.05M | -14.58M | -12.72M | -13.15M | -12.33M | -12.09M | -11.46M | -12.56M | -13.94M | -12.75M | -11.21M | -7.89M | -4.8M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 1.86M | 2.68M | 3.44M | 4.12M | 4.49M | 4.07M | 3.77M | 3.35M | 3.34M | 3.25M | 3.3M | 3.25M | 5.82M | 7.36M | 6.74M | 6.27M | 3.18M | 1.25M |
Other Working Capital | -33.38K | -176.73K | 206.06K | -50.87K | -74.11K | 925.79K | 1.01M | 2.27M | 2.62M | 1.47M | 1.25M | 662.42K | -1.27M | 302.96K | 141.28K | -377.96K | 1.26M | -368.22K |
Other Non-Cash Items | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -66.5K | 850.26K | 850.26K | 850.26K | 916.76K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | -22.47K | -176.73K | 284.09K | -19.09K | 3.92K | 1.05M | 1.01M | 2.27M | 2.62M | 1.47M | 1.25M | 662.42K | -1.27M | 302.96K | 141.28K | -377.96K | 1.26M | -368.22K |
Operating Cash Flow | -8.16M | -9.37M | -10.38M | -12.33M | -12.23M | -10.93M | -9.8M | -7.1M | -7.19M | -7.6M | -7.54M | -7.55M | -8M | -6.34M | -5.01M | -4.47M | -2.6M | -3M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 66.5K |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 2.48M | n/a | 210.2K | 4.83M | 8.37M | 8.37M | 8.16M | 3.54M | 3.7M | 3.7M | 3.7M | 3.7M | n/a | n/a | n/a | n/a | n/a | n/a |
Financial Cash Flow | 7.87M | 5.09M | 6.62M | 11.04M | 9.45M | 12.67M | 8.16M | 3.54M | 7.24M | 3.7M | 3.7M | 3.7M | n/a | 14.8M | 14.8M | 15.53M | 17.72M | 4.04M |
Net Cash Flow | -296.73K | -4.28M | -3.77M | -1.29M | -2.78M | 1.74M | -1.64M | -3.56M | 53.64K | -3.9M | -3.85M | -3.85M | -8M | 8.45M | 9.78M | 11.05M | 15.12M | 1.04M |
Free Cash Flow | -8.16M | -9.37M | -10.38M | -12.33M | -12.23M | -10.93M | -9.8M | -7.1M | -7.19M | -7.6M | -7.54M | -7.55M | -8M | -6.34M | -5.01M | -4.47M | -2.6M | -3M |